Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-08-18
2011-11-15
Seaman, D M (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S281000
Reexamination Certificate
active
08058274
ABSTRACT:
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides heterocycles, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, seizure, retinal degeneration, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety, neuronal degeneration and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
REFERENCES:
patent: 7105534 (2006-09-01), Beatch et al.
patent: 2005/0250833 (2005-11-01), Attali et al.
patent: 2007/0099899 (2007-05-01), Atwal et al.
patent: 2009/0137595 (2009-05-01), Sakai et al.
patent: 2009/0163489 (2009-06-01), Booker et al.
patent: 2010/0029619 (2010-02-01), Uchikawa et al.
patent: 2010/0240663 (2010-09-01), Christos et al.
patent: 2006054652 (2006-05-01), None
patent: 2007095588 (2007-08-01), None
patent: 2008030579 (2008-03-01), None
patent: WO 2009/026254 (2009-02-01), None
patent: WO 2009/136663 (2009-11-01), None
Mourad et al., Journal of Heterocyclic Chemistry (1993), 30(5), 1365-72.
Mourad et al., Journal of Heterocyclic Chemistry (1992), 29(6), 1583-92.
Ackerman, M.J. et al., “Mechanisms of Disease,”The New England Journal of Medicine,May 29, 1997, vol. 336, No. 22, pp. 1575-1587.
Biervert, C. et al., “A Potassium Channel Mutation in Neonatal Human Epilepsy,”Science,Jan. 16, 1998, vol. 279, No. 403, pp. 403-406.
Blatz, A.L. et al., “Single apamin-blocked Ca-activated K+channels of small conductance in cultured rat skeletal muscle,”Nature,Oct. 23, 1986, vol. 323, pp. 718-720.
Daniel, S. et al., “Screening for Potassium Channel Modulators by a High Through-Put 86-Rubidium Efflux in a 96-Well Microtiter Plate,”Journal of Pharmacological Methods,1991, vol. 25, pp. 185-193.Daniel et al.,J. Pharmacol. Meth.,1991, vol. 25, pp. 185-193.
Hamil, O.P. et al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,”Pflügers. Archive.,1981, vol. 391, pp. 85-100.
Holevinsky, K.O. et al., “ATP-sensitive K+ Channel Opener Acts as a Potent Cl- Channel Inhibitor in Vascular Smooth Muscle Cells,”The Journal of Membrane Biology,1994, vol. 137, pp. 59-70.
International Search Report mailed on Nov. 12, 2008, for International Application No. PCT/US08/73519 filed on Aug. 18, 2008, 2 pages.
Joiner, W.J. et al., “Formation of intermediate-conductance calcium-activated potassium channels by interaction of Slack and Slo subunits,”Nature Neuroscience,Oct. 1998, vol. 1, No. 6, pp. 462-469.
Kim, S.H. et al., “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,”Pain,1992, vol. 50, pp. 355-363.
Leppert, M. et al., “Benign familial neonatal convulsions linked to genetic markers on chromosome 20,”Nature,Feb. 16, 1989, vol. 337, pp. 647-648.
Main, M.J. et al., “Modulation of KCNQ2/3 Potassium Channels by the Novel Anticonvulsant Retigabine,”Molecular Pharmacology,2000, vol. 58, pp. 253-262.
Meera, P. et al., “Large conductance voltage- and calcium-dependent K+channel, a distinct member of voltage-dependent ion channels with seven N-terminal transmembrane segments (S0-S6), an extracellular N terminus, and an intracellular (S9-S10) C terminus,”Proc. Natl. Acad. Sci. USA,Dec. 1997, vol. 94, No. 25, pp. 14066-14071.
Park, YB., “Ion selectivity and gating of small conductance Ca2+-activated K+channels in cultured rat adrenal chromaffin cells,”Journal of Physiology,1994, vol. 481, No. 3, pp. 555-570.
Robbins, J. et al., “Kinetic and Pharmacological Properties of the M-Current in Rodent Neuroblastoma × Glioma Hybrid Cells,”Journal of Physiology,1992, vol. 451, pp. 159-185.
Sanguinetti, M.C. et al., “Coassembly of KvLQT1 and minK (IsK) proteins to form cardiacIKspotassium channel,”Nature,Nov. 7, 1996, vol. 384, pp. 80-83.
Schreiber, M. et al., “Slo3, a Novel pH-sensitive K+Channel from Mammalian Spermatocytes,”The Journal of Biological Chemistry,Feb. 6, 1998, vol. 273, No. 6, pp. 3509-3516.
Schroeder, B.C. et al., “KCNQ5, a Novel Potassium Channel Broadly Expressed in Brain, Mediated M-type Currents,”The Journal of Biological Chemistry,Aug. 4, 2000, vol. 275, No. 31, pp. 24089-24095.
Selyanko, A.A. et al., “Two Types of K+Channel Subunit, Erg1 and KCNQ2/3, Contribute to the M-Like Current in a Mammalian Neuronal Cell,”The Journal of Neuroscience,Sep. 15, 1999, vol. 19, No. 18, pp. 7742-7756.
Selyanko, A.A. et al., “Dominant-Negative Subunits Reveal Potassium Channel Families That Contribute to M-Like Potassium Currents,”The Journal of Neuroscience,2002, vol. 22, RC212, 5 pages.
Shi, G. et al., “β Subunits Promote K+ Channel Surface Expression through Effects Early in Biosynthesis,”Neuron,Apr. 1996, vol. 16, pp. 843-852.
Vestergaard-Bogind, B. et al., “Single-File Diffusion through the Ca2+-Activated K+Channel of Human Red Cells,”The Journal of Membrane Biology,1988, vol. 88, pp. 67-75.
Wang, H-S. et al., “KCNQ2 and KCNQ3 Potassium Channel Subunits: Molecular Correlates of the M-Channel,”Science,Dec. 4, 1998, vol. 282, pp. 1890-1893.
Wei, A. et al., “Eight Potassium Channel Families Revealed by the C.elegansGenome Project,”Neumpharmacology,1996, vol. 35, No. 7, pp. 805-829.
Acero-Alarcon, A. et al., “Unusual Ring Closure Reaction of Amides with Pyrimidines: Novel Stereoselective Synthesis of Hexahydroimidazo[1,2-c]pyrimidines,”Synthesis,vol. 12, 1999, pp. 2124-2130.
Butler, A. et al., “mSlo,a complex mouse gene encoding “Maxi” calcium-activated potassium channels,”Science,1993, vol. 261, pp. 221-224.
Database Registry (online) Chemical Abstracts Service, Columbus, OH, US; Nov. 11, 2007, XP002629766, Database accession No. 952958-52-0 [abstract].
Heinemann, S. H. et al., “Functional characterization of Kv channel beta-subunits from rat brain,”J. Physiol.,1996, vol. 493, pp. 625-633.
Kananura, C. et al., “The new voltage gated potassium channel KCNQ5 and neonatal convulsions,”Neuroreport,2000, vol. 11, No. 9, pp. 2063-2067.
Kubisch, C. et al., “KCNQ4, a Novel Potassium Channel Expressed in Sensory Outer Hair Cells, Is Mutated in Dominant Deafness,”Cell,1999, vol. 96, No. 3, pp. 437-446.
Wickenden, A et al., “Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells,”Br. J. Pharma,2001, vol. 132, pp. 381-384.
Relevant portion of International Search Report for related Application No. PCT/US2011/023444, mailed Apr. 14, 2011.
Amato George S.
Atkinson Robert N.
Barolli Maria Graciela
Christos Thomas Eugene
Suto Mark J.
Icagen Inc.
Morgan & Lewis & Bockius, LLP
Rahmani Niloofar
Seaman D M
LandOfFree
Heterocycles as potassium channel modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocycles as potassium channel modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocycles as potassium channel modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4311380